Related Experiment Video
Updated: May 9, 2026
11:13
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives
R Téllez-Sanz1, L García-Fuentes, A Vargas-Berenguel
1Department of Chemistry and Physics, University of Almeria, Spain.
Current Medicinal Chemistry
|July 10, 2013
Summary
Researchers explored potent inhibitors for human galectin-3 (hGal-3), a key target in diseases like cancer and heart failure. Understanding inhibitor selectivity is crucial for developing new hGal-3 targeted therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Human galectin-3 (hGal-3) is implicated in numerous diseases, including cancer and heart failure.
- Its unique structural properties and involvement in cellular functions make it a significant therapeutic target.
- Galectins bind β-galactosides, posing challenges for selective inhibitor design.
Purpose of the Study:
- To review the chemical features of potent hGal-3 inhibitors.
- To elucidate the structural basis for inhibitor selectivity.
- To guide the rational design of novel hGal-3 targeted drugs.
Main Methods:
- Literature review of published studies on hGal-3 inhibitors.
- Analysis of chemical structures and binding affinities.
- Examination of structure-activity relationships and selectivity profiles.
Main Results:
- Several classes of potent hGal-3 inhibitors have been identified.
- Key chemical moieties contributing to potency and selectivity have been characterized.
- Structural insights reveal specific interactions crucial for targeting hGal-3.
Conclusions:
- Rational drug design for hGal-3 requires understanding both inhibitor potency and selectivity.
- Detailed analysis of existing inhibitors provides a foundation for developing effective therapeutics.
- Targeting hGal-3 holds promise for treating various human diseases.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...